Evaluation of the pharmacoeconomics of alprostadil in pharmacotherapeutic schemes for cerebral infarction
- VernacularTitle:前列地尔在脑梗死治疗中的药物经济学评价
- Author:
Xiaojun SONG
;
Ji SHEN
- Publication Type:Journal Article
- Keywords:
Pharmacoeconomics;
Cerebral infarction;
Alprostadil;
Pharmacotherapy
- From:
Journal of Medical Postgraduates
2003;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the curative effects and the economic effects of Alprostadil in Pharmacotherapeutic Schemes for Cerebral Infarction. Methods:118 cases of cerebral infarction, admitted from March 2001 to March 2003, were collected and divided into two groups: Alprostadil was given to group Ⅰ, Alprostadil was not given to group Ⅱ. Data was evaluated using the pharmacoeconomics cost effectiveness analysis. Results: The costs of two groups were 13 826.13 and 7 884.55 yuan respectively. The effective rates of two groups were 92.89% and 80.33% respectively. The cost-effective rates of two groups were 148.70 and 98.15 yuan / per unit of effective. It cost 469.69 yuan for group Ⅰ to increase per unit of effective above group Ⅱ. Conclusion: GroupⅡ had lower cost- effective ratio, and groupⅠ had higher effective rate. If patients care about effectiveness more than cost, it maybe useful to take groupⅠ.
